OmniScope Multi-Modal Full-Body Scanner Gets FDA Clearance: One 30-Minute Scan Screens for 12 Early Cancers and Chronic Diseases

OmniScope Multi-Modal Full-Body Scanner Gets FDA Clearance: One 30-Minute Scan Screens for 12 Early Cancers and Chronic Diseases

On July 23, 2028, Israeli medical imaging company Prenuvo announced that its OmniScope multi-modal full-body scanning system received FDA 510(k) clearance. In a single 30-minute scan, OmniScope can simultaneously complete screening for 12 types of early-stage cancer, coronary artery calcium scoring, and preliminary assessment of neurodegenerative brain diseases.

OmniScope's technical innovation lies in integrating three imaging modalities -- high-field MRI, low-dose PET, and photoacoustic imaging -- into a continuous scanning workflow. The patient lies on a mobile examination table that sequentially passes through three imaging zones. AI systems fuse data from all three modalities in real time during the scan, generating a full-body multi-parameter imaging map.

Prenuvo's VP of Clinical Research Sarah Kim said in a phone interview: "Traditional health screenings are fragmented -- blood work is one thing, imaging is another, with no connection between them. OmniScope aims to provide a one-time, whole-body systems-level assessment."

In clinical trials involving 14,000 subjects, OmniScope achieved early cancer detection sensitivity of 91.3% and specificity of 96.7%. Detection rates for stage I lung cancer, liver cancer, and pancreatic cancer were 89%, 93%, and 82% respectively -- cancers that are typically only discovered at late stages with conventional screening.

A single OmniScope scan costs $2,500 and is currently not covered by insurance. Prenuvo says it is negotiating with UnitedHealth Group and Aetna to include it in premium health screening packages.

The system's rollout has also sparked debate about overdiagnosis. Harvard Medical School radiology professor James Mitchell noted that high-sensitivity full-body screening will discover a large number of clinically insignificant incidental findings -- small nodules, benign cysts, non-progressing lesions -- leading to unnecessary follow-up tests and patient anxiety. Prenuvo responds that OmniScope's AI system includes a clinical significance assessment module that labels low-risk incidental findings as "observe and follow up" rather than "requires further investigation."